What question did this study set out to answer?

To identify clinical characteristics and mortality predictors among HIV/AIDS patients with Mycobacterium tuberculosis bacteraemia.

April 1, 2026

View Full Paper

Clinical profile and predictors of mortality among people living with HIV/AIDS with Mycobacterium tuberculosis detected in blood or bone marrow at a tertiary hospital in Northeast Brazil

ASAdriano Monteiro da SilvaUniversidade Estadual do Ceará PGPedro Italo Oliveira Gomes IMIvna Felice Silva Matos

Key Points

To identify clinical characteristics and mortality predictors among HIV/AIDS patients with Mycobacterium tuberculosis bacteraemia.
Analyzed clinical profiles of HIV/AIDS patients with Mycobacterium tuberculosis detected in blood or bone marrow.
Measured lymphocyte, platelet, and CD4+ T-lymphocyte counts, and urea levels.
Assessed the relationship between CD4+ T-lymphocyte count and mortality.
Higher mortality associated with lower lymphocyte, platelet, and CD4+ T-lymphocyte counts.
CD4+ T-lymphocyte count below 32 cells/mm³ linked to increased mortality.
Survivors more frequently received a regimen of rifampicin, isoniazid, pyrazinamide, and ethambutol.

Abstract

Mycobacterium tuberculosis bacteraemia is a severe manifestation of tuberculosis in people living with human immunodeficiency virus acquired immune deficiency syndrome, associated with high mortality. We found patients with fatal outcomes had significantly lower lymphocyte, platelet, and CD4+ T-lymphocyte counts, and higher urea levels (p 3 was independently associated with mortality (p = 0.005). The oral rifampicin, isoniazid, pyrazinamide, and ethambutol regime was more frequent among survivors. Social vulnerability factors were common but not independently associated with mortality.

AIに質問

Bookmark

View Full Paper

Cite This Study

Silva et al. (Mon,) studied this question.

synapsesocial.com/papers/69ccb6b416edfba7beb8871e https://doi.org/https://doi.org/10.1177/00494755261435265

AIに質問

Bookmark

View Full Paper